Quick Answer
MAIA Biotechnology, Inc. reported Research And Development Expense of $10.01 million for the year ending 2024.
- MAIA Biotechnology, Inc. showed a decrease of -9.9% in Research And Development Expense from 2023 to 2024.
- This data is from MAIA Biotechnology, Inc.'s annual report (Form 10-K), filed with the SEC on March 21, 2025.
- XBRL data for this metric is available from 2021 to 2024 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $644.0 thousand | Q3 2021: $1.08 million | Q1 2022: $2.08 million | Q2 2022: $2.12 million | Q3 2022: $2.34 million | Q1 2023: $2.20 million | Q2 2023: $2.60 million | Q3 2023: $2.60 million | Q1 2024: $2.32 million | Q2 2024: $2.05 million | Q3 2024: $2.67 million | Q1 2025: $3.20 million.
- Over the full 4 years of available data (2021 to 2024), MAIA Biotechnology, Inc.'s Research And Development Expense has grown by 186.2%.
- Historical annual values: Fiscal year 2024: $10.01 million | Fiscal year 2023: $11.11 million | Fiscal year 2022: $8.93 million | Fiscal year 2021: $3.50 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: